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Abstract
The simian–human immunodeficiency virus (SHIV)/ macaque model for human immunodeficiency virus type 1 has become a useful tool to
assess the role of Vpu in lentivirus pathogenesis. In this report, we have mutated the two phosphorylated serine residues of the HIV-1 Vpu to glycine
residues and have reconstructed a SHIV expressing this nonphosphorylated Vpu (SHIVS52,56G). Expression studies revealed that this protein was localized
to the same intracellular compartment as wild-type Vpu. To determine if this virus was pathogenic, four pig-tailed macaques were inoculated with
SHIVS52,56G and virus burdens and circulating CD4 T cells monitored up to 1 year. Our results indicate that SHIVS52,56G caused rapid loss in the
circulating CD4 T cells within 3 weeks of inoculation in one macaque (CC8X), while the other three macaques developed no or gradual numbers of
CD4 T cells and a wasting syndrome. Histological examination of tissues revealed that macaque CC8X had lesions in lymphoid tissues (spleen, lymph
nodes, and thymus) that were typical for macaques inoculated with pathogenic parental SHIVKU-1bMC33 and had no lesions within the CNS. To rule out
that macaque CC8X had selected for a virus in which there was reversion of the glycine residues at positions 52 and 56 to serine residues and/or
compensating mutations occurred in other genes associated with CD4 down-regulation, sequence analysis was performed on amplified vpu sequences
isolated from PBMC and from several lymphoid tissues at necropsy. Sequence analysis revealed a reversion of the glycine residues back to serine residues
in this macaque. The other macaques maintained low virus burdens, with one macaque (P003) developing a wasting syndrome between months 9 and
11. Histological examination of tissues from this macaque revealed a thymus with severe atrophy that was similar to that of a previously reported macaque
inoculated with a SHIV lacking vpu (Virology 293, 2002, 252). Sequence analysis revealed no reversion of the glycine residues in the vpu sequences
isolated from this macaque. These results contrast with those from four macaques inoculated with the parental pathogenic SHIVKU-1bMC33, all of which
developed severe CD4 T cell loss within 1 month after inoculation. Taken together, these results indicate that casein kinase II phosphorylation sites of
Vpu contributes to the pathogenicity of the SHIVKU-1bMC33 and suggest that the SHIVKU-1bMC33/pig-tailed macaque model will be useful in analyzing
amino acids/domains of Vpu that contribute to the pathogenesis of HIV-1.
© 2003 Elsevier Science (USA). All rights reserved.
Introduction
Viral protein U (Vpu) is a small transmembrane protein
that is encoded by human immunodeficiency virus type 1
(HIV-1) and is synthesized off a bicistronic mRNA that also
codes for the HIV-1 envelope glycoprotein (Schwartz et al.,
1990). Previous studies have shown that Vpu is localized to
the rough endoplasmic reticulum/Golgi complex and has
several functions in the virus replication cycle (Kimura et
al., 1994). Vpu has been shown to interact with newly
synthesized CD4, re-translocate this molecule across the
RER membrane, and target it for destruction via the protea-
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some pathway (Fujita et al., 1997; Schubert et al., 1998).
Certain highly conserved domains have been shown to be
essential to Vpu-mediated CD4 down-regulation. Previous
studies in our laboratory have indicated that certain protein
domains of Vpu are highly conserved in all strains exam-
ined (McCormick-Davis et al., 2000a). The most exten-
sively studied of these domains is the hinge region contain-
ing the two casein kinase II phosphorylation sites and
previous studies have shown that phosphorylation of both of
these serine residues (at positions 52 and 56) are essential
for CD4 down-regulation and are highly conserved in group
M and O HIV-1 isolates (Paul and Jabbar, 1997; Raja and
Jabbar, 1997; McCormick-Davis et al., 2000a). In addition
to CD4 down-regulation from the surface, Vpu has also
been shown to facilitate virion release from infected cells
and this property of Vpu has been associated with the
transmembrane domain which has been reported to have an
ion channel activity (Ewart et al., 1996; Schubert et al.,
1996b; Sansom et al., 1998).
While studies have established the role of the phos-
phoserines in CD4 degradation in cell culture studies, no
studies have examined the function of the casein kinase II
sites in the a relevant animal model of CD4 T cell loss.
The simian– human immunodeficiency virus (SHIV) is a
chimeric virus that contains the tat, rev, vpu, and env
genes in a genetic background of SIVmac239. We and
others have developed pathogenic SHIVs that are capable
of causing massive CD4 T cell loss and AIDS in both
pig-tailed and rhesus macaques (Joag et al., 1996;
Reimann et al., 1996; Luciw et al., 1999; Stephens et al.,
2002). Since Vpu is found only in HIV-1 and SIVcpz
(McCormick-Davis et al., 2000a), the pathogenic SHIVs
have enormous potential in examining the role of Vpu in
the pathogenesis in the context of a macaque model
system. Previously, we have constructed a pathogenic
molecular clone of SHIV known as SHIVKU-1bMC33,
which has an intact vpu gene and encodes for functional
Vpu protein (McCormick-Davis et al., 2000b; Stephens
et al., 2002). In the present study, we examined the role
of casein kinase II phosphorylation of two conserved
serine residues on the pathogenesis of SHIVKU-1bMC33 in
pig-tailed macaques. Our results indicate that the two
casein kinase II phosphorylation sites of Vpu contribute
to the pathogenicity SHIVKU-1bMC33/pig-tailed macaque
model of CD4 T cell loss and provide additional evi-
dence that this protein enhances the pathogenicity of
HIV-1. Thus, this is the first report showing a role for
these sites in vivo.
Results
The VpuEGFP protein
To determine if the VpuEGFP fusion protein had a Mr
that was comparable with previous reports, human 293 cells
were transfected and at 48 h either radiolabeled for immune
precipitation studies or examined by confocal fluorescence
microscopy. Immune precipitation analysis revealed that
following transfection of 293 cells with pcvpuEGFP, a pro-
tein with a Mr of approximately 43 kDa, was immune
precipitated using a polyclonal EGFP antibody (Fig. 1).
Transfection of cells with pcEGFP resulted in a protein with
a Mr of approximately 27,000 (data not shown). As previous
studies have reported that the size of the virus expressed
protein had a Mr of 16,000, the finding of the protein with
an Mr of 43,000 is close to what would be expected for the
size of the fusion protein. Virus-expressed Vpu has been
shown to be phosphorylated by casein kinase II and this
phosphorylation has been shown to be essential to CD4
down-regulation. We determined if the VpuEGFP protein
was phosphorylated by generating a site-directed mutant
in which the two serine residues at positions 52 and 56
were changed to glycine residues. This plasmid,
pcvpuS52,56GEGFP, was transfected into 293 cells and ra-
diolabeled, and the expressed protein immune precipitated
from cell lysates. As shown in Fig. 1A, the Mr of the
VpuS52,56GEGFP protein was slightly faster when compared
to the intact VpuEGFP, providing indirect evidence that this
protein was phosphorylated. To confirm that the VpuEGFP
was phosphorylated, cells were transfected with pcEGFP,
pcvpuEGFP, or pcvpuS52,56GEGFPand at 48 h metabolically
Fig. 1. Alteration of the casein kinase II phosphorylation sites results in
altered mobility and a lack of phosphorylation of the VpuEGFP fusion
protein. The two phosphorylated serine residues of Vpu were changed to
glycine residues using site-directed mutagenesis techniques as described
under Materials and Methods. (A) 293 cells were transfected with
pcvpuEGFP, pcvpuS52,56GEGFP, or pcDNA3.1() vectors as described in
the text. At 48 h, cells were starved for methionine and cysteine and
radiolabeled for 12 h with [35S]methione/cysteine. Cells were processed
and EGFP containing proteins immune precipitated using an -EGFP
serum and analyzed by SDS–PAGE as described. Lane 1, EGFP proteins
immune precipitated from pcvpuS52,56GEGFP-transfected cells; lane 2,
EGFP proteins immune precipitated from pcvpuEGFP- transfected cells;
lane 3, EGFP proteins immune precipitated from pcDNA3.1()-trans-
fected cells; sizes of molecular weight markers are shown to the side of the
gel. (B) 293 cells were transfected with pcvpuEGFP, pcvpuS52,56GEGFP, or
pcEGFP as described under Material and Methods. At 48 h, cells were
washed and metabolically labeled in phosphate-free medium for 5 h with
[32P]orthophosphate. Cells were processed and EGFP containing proteins
immune precipitated using an -EGFP serum and analyzed by SDS–PAGE
as described. Lane 1, EGFP proteins immune precipitated from
pcvpuEGFP-transfected cells; lane 2, EGFP proteins immune precipitated
from pcvpuS52,56GEGFP-transfected cells; lane 3, EGFP proteins immune
precipitated from pcDNA3.1()-transfected cells.
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labeled with [32P]-orthophosphate. Cells were washed and
lysed and EGFP containing proteins immune precipitated
using a polyclonal EGFP antibody. As shown in Fig. 1B,
32P-labeled VpuEGFP proteins were only immune precipi-
tated from cultures transfected with pcvpuEGFP, providing
direct evidence that the VpuEGFP protein was phosphory-
lated at the casein kinase II sites.
A Vpu protein with the casein kinase II sites is localized
to the same intracellular compartment in cells
We used the vectors expressing the VpuEGFP and
VpuS52,56GEGFP to analyze intracellular localization. When
transfected into 293 cells, the wild-type VpuEGFP protein
was localized to RER/Golgi complex compartments and
was not observed on the cell surface to any significant
extent, similar to the reported findings for the virus-ex-
pressed protein (Kimura et al., 1994). Expression of the
VpuS52,56GEGFP in this expression system is shown in Fig.
2 and shows that the VpuS52,56GEGFP protein had the same
intracellular localization as the unmodified VpuEGFP pro-
tein, demonstrating that the casein kinase II sites were not
required for Vpu targeting to the RER/Golgi compartments.
A Vpu protein with the casein kinase II sites prevents
CD4 expression on the cell surface
Using the VpuEGFP reporter, we also analyzed the abil-
ity of VpuS52,56GEGFP to prevent CD4 expression on the
cell surface. As shown in Figs. 3A–D, HeLa CD4 cells
transfected with the VpuEGFP vector clearly abolished cell
surface expression of CD4 (Table 1). In contrast, transfec-
tion of cultures with the pcvpuS52,56GEGFP vector still re-
sulted in the expression of CD4 on the cell surface and was
similar to cultures transfected with pcEGFP, which ex-
presses only EGFP reporter protein (Table 1). These results
indicate that mutation of the serine residues at positions 52
and 56 to glycine residues abolished the ability of Vpu to
prevent CD4 from being expressed on the cell surface.
Inoculation of four pig-tailed macaques with
SHIVKU-1bMC33 resulted in a rapid loss of circulating
CD4 T cells in four of four pig-tailed macaques
All four macaques inoculated with parental SHIVKU-
1bMC33 exhibited a severe loss in their circulating CD4 T
cells by 1 month postinoculation that was main-
tainedthroughout the course of their 6-month infection (Fig.
4A). Examination of the plasma virus loads from two of
these macaques (CM4G and CM4K) revealed a high num-
ber of viral copies in the plasma early after inoculation,
which was maintained above 10,000 copies throughout the
course of their 6-month infection (Fig. 4B). Histological
examination of tissues at necropsy revealed the typical lym-
phoid depletion in the thymus, spleen, and lymph nodes that
is associated with pathogenic SHIVKU-1bMC33 infection
(Stephens et al., 2002). Examination of visceral organs for
viral sequences revealed that eight of nine visceral organs
were positive for viral gag sequences from macaques
CM4G and CM4K (data not shown) and that amplification
of 2-LTR circles, indicative of recent infection, revealed
that six of nine visceral organs were positive (Fig. 4C).
Histological examination of 15 regions of the CNS from
these four macaques revealed no lesions consistent with
lentiviral encephalitis. Of the 15 regions of the CNS exam-
ined from macaques CM4G and CM4K, no regions and 1
region were positive for 2-LTR sequences, respectively
(data not shown), indicating that the virus was poorly neu-
roinvasive in these macaques.
Inoculation of four pig-tailed macaques with SHIVS52,56G
resulted in a rapid loss of circulating CD4 T cells in
one of four pig-tailed macaques
We determined whether the SHIVS52,56G replicated with
the same kinetics as the parental SHIVKU-1bMc33. Equivalent
amounts of each virus were used to inoculate C8166 cul-
tures and culture supernatants assayed for p27 over a 10-day
period. The SHIVS52,56G virus replicated with similar kinet-
ics as the parental SHIVKU-1bMC33 (data not shown). We
next inoculated four pig-tailed macaques (CC8X, CC8V,
P003, and P017) with SHIVS52,56G. The circulating CD4 T
cell numbers and plasma virus loads following inoculation
are shown in Figs. 5A and B. Macaque CC8X developed a
severe loss in its circulating CD4 T cells soon after inoc-
ulation (15 cells/1 by 4 weeks postinoculation) and this loss
was maintained throughout the course of the 18-week in-
fection. The severe loss of CD4 T cells in this macaque
was similar to that in macaques inoculated with the unmod-
ified SHIVKU-1bMC33 (Fig. 4). Examination of plasma viral
loads by real time RT–PCR revealed that the macaque
CC8X had the highest viral loads throughout the course of
the infection with SHIVS52,56G. At necropsy, histological
examination of the tissues revealed severe lymphoid deple-
Table 1
Results of transfection of HeLa CD4 cells with vectors expressing
EGFP, VpuEGFP, or VpuS52,56GEGFP on cell surface CD4 expression
Vector
EGFP VpuEGFP VpuS52,56GEGFP
% HeLa cells positive
for CD4
85 81 79
% HeLa cell positive
for EGFP expression
20 10% 12%
% HeLa cells positive
for EGFP cell
surface CD4
expressiona
100 0% 100%
a Number of EGFP, VpuEGFP, or VpuS52,56GEGFP expressing HeLa
CD4 cells counted from three experiments exceeded 400.
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tion in thymus, spleen, and lymph nodes of CC8X (Fig. 6),
which is typical of pig-tailed macaques inoculated with
pathogenic SHIVKU-1bMC33. Examination of 14 regions of
the CNS from CC8X revealed no lesions consistent with
lentiviral encephalitis. Examination of tissue DNAs from
CC8X using PCR that amplified the viral gag revealed that
eight of eight visceral organs were positive (data not shown)
and amplification of 2-LTR circles, indicative of recent
infection, was detected in six of ten visceral organs, with
only the heart, kidney, liver, and pancreas negative (Fig. 7).
Of the 14 regions of the CNS examined, only 3 regions were
positive for gag sequences (motor cortex, parietal cortex,
and midbrain), with the midbrain also being positive for the
presence of 2-LTR circle sequences (data not shown), indi-
cating that the virus was poorly neuroinvasive in this ma-
caque.
The serine to glycine changes in vpu were not stable
throughout the course of infection of macaque CC8X
Because of the severe loss of CD4 T cells in CC8X, one
possibility was that there was a selection for mutations in
Fig. 2. The VpuS52,56GEGFP is localized to the same intracellular compartment as the unmodified VpuEGFP. 293 cells were transfected with pcEGFP,
pcvpuEGFP, and pcvpuS52,56GEGFP vectors as described in the text and at 48 h examined by fluorescence confocal (A, D, and G), phase–contrast (B, E, and
H) microscopy. Panels C, F, and I merge the confocal and phase–contrast images. (A–C) 293 cells transfected with pcEGFP. (D–F) 293 cells transfected
with pcvpuEGFP. (H and I) 293 cells transfected with vpuS52,56GEGFP.
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the vpu that resulted in the reversion of the glycine residues
at positions 52 and 56 back to serine residues. In order to
test this hypothesis, vpu was amplified by PCR from PBMC
DNA isolated at 3, 8, and 12 weeks and at necropsy (18
weeks) from macaque CC8X and directly sequenced. The
bulk PCR sequencing results were confirmed for CC8X and
CC8V by cloning and sequencing individual vpu clones. In
addition, we also examined the vpu sequences from the
mesenteric lymph node, thymus and spleen tissues at nec-
ropsy. The results of the sequence analysis are shown in
Figs. 8A and B. Direct sequence analysis of vpu amplified
from PBMC DNA by nested PCR revealed that the glycine
change at position 52 was stable at 3 weeks postinoculation.
Direct sequence analysis of vpu amplified from PBMC
DNA at 3 weeks revealed the presence of an A (which
would code for a serine at position 56) and G (coding for the
input glycine the same position) at position 169 of the gene.
However, this was not confirmed by sequencing of individ-
ual vpu clones. At 8 weeks, direct sequencing of PCR
products and individual vpu clones revealed changes at both
position 157 (G to A resulting in a serine) and position 169.
These results were also seen at 12 and 18 weeks (necropsy)
and confirmed in the analysis of vpu genes in the spleen,
lymph nodes, and thymus. In order to rule out that this
macaque might have been inoculated with a stock that was
contaminated with the parental SHIVKU-1bMC33, the vpu
gene in the virus stocks used to inoculate the macaques was
extensively analyzed. Only the vpu gene coding for glycines
at positions 52 and 56 was found. Sequence analysis of the
PBMC and lymphoid tissues from the other three macaques
did not reveal the reversions observed with CC8X.
The glycine to serine reversions were found in viruses
recovered from infectious viruses recovered from
macaque CC8X
As we were able to detect reversions in vpu at later times
after inoculation by amplification of the gene from tissue
DNAs, we determined if these reversions were present in
viruses recovered from various organs at necropsy. Culture
supernatants were recovered by cocultures of cells isolated
from the PBMC, thymus, spleen, and mesenteric lymph
Fig. 3. The VpuS52,56GEGFP is does not prevent CD4 from being expressed on the cell surface. HeLa CD4 cells, which express CD4, were transfected with
pcEGFP, pcvpuEGFP, or pcvpuS52,56GEGFP vectors. At 48 h posttransfection, cells were stained for surface CD4 using -CD4-RITC antibody followed by
fixation with 1% formalin. Cells were analyzed by phase–contrast microscopy (A,E, and I) or fluorescence microscopy using a fluorescein filter (indicating
VpuEGFP expression; B,F, and J) or a rhodamine filter (for CD4 surface expression; C, G, and K) or dual filters (for expression of VpuEGFP and CD4
expression; D, H, and L). (A–D) Transfection with the pcEGFP construct. (E–H) Transfection with the pcvpuEGFP construct. (I–L) Transfection with the
pcvpuS52,56GEGFP construct.
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nodes with C8166 cells. The harvested supernatants were
filtered and used to inoculate fresh C8166 cultures. The cells
from these cultures were harvested at 4 days postinocula-
tion, the DNA was isolated, and the vpu gene amplified.
Sequence analysis of the PCR products indicated that the
reversions at both positions in vpu could be detected in the
viruses isolated from the PBMC, lymph node, and spleen
but not in virus isolated from the thymus (Fig. 8B). Virus
harvested from CC8V, P017, and P003 at necropsy main-
tained glycine residues at positions 52 and 56.
Fig. 4. SHIVKU-1bMC33 was pathogenic for four of four macaques 2000 (F), 2001 (), CM4G (E), and CM4K (Œ). (A) Macaques were inoculated with
SHIVKU-1bMC33 and circulating CD4 T cells determined at various times postinoculation. (B) Virus RNA levels were performed on RNA extracted from
500 liters of EDTA-treated plasma. Samples were subjected to real-time RT–PCR and Taqman probe homologous to the SIV gag gene. Standard curves were
generated using five dilutions of viral RNA of known concentration. (C) Viral 2-LTR sequences were amplified using PCR from DNA samples from visceral
organs from macaque CM4K. The order of the gels is shown in C: lane 1, molecular weight markers (100 bp); lane 2, positive control—lymph node of
macaque 50O; lane 3, negative control—lymph node from an uninoculated macaque; lane 4, lung; lane 5, liver; lane 6, kidney; lane 7, axillary lymph node;
lane 8, mesenteric lymph node; lane 9, pancreas; lane 10, small intestine; lane 11, spleen; lane 12, thymus.
Fig. 5. Circulating CD4 T cells and plasma virus loads following inoculation of pig-tailed macaques with SHIVS52,56G. (A) The levels of circulating CD4
T cells in macaques CC8X (Œ), CC8V (}), P003 (F), and P017 () following inoculation with SHIVS52,56G. (B) The plasma virus loads in macaques CC8X
(Œ), CC8V (}), P003 (F), and P017 () following inoculation with SHIVS52,56G.
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Compensating mutations in Env and Nef were not
observed after inoculation with SHIVS52,56G
Another possibility that had to be considered was that
because of the mutations engineered in vpu, virus might
have been selected for mutations in other viral genes in-
volved in CD4 down-regulation, namely, env and nef, that
would have compensated for the lack of a functional Vpu.
We amplified, cloned, and sequenced the gp120 and Nef
regions of the viral genome from PBMCs at 3, 8, and 18
weeks as well as from lymph node and spleen tissue at
necropsy. The results of the sequence analysis indicated that
at necropsy, there were no consensus amino acid substitu-
tions in either the gp120 or nef genes, which was the time
when CC8X had developed a massive loss of circulating
CD4 T cells (data not shown).
Macaque CC8V, P003, and P017 maintained low virus
burdens
In contrast to macaque CC8X, macaques CC8V, P003,
and P017 did not develop a significant loss of CD4 T cells
over a 9- to 11-month period following inoculation with
SHIVS52,56G (Fig. 4A). This was also reflected in the plasma
virus loads when compared to CC8X (Fig. 4B). Macaque
CC8V was sacrificed at 40 weeks postinoculation to deter-
Fig. 6. Histopathology of macaques CC8X, CC8V, and P003. Micrographs of thymus (A,D, and G), spleen (B, E, and H), and mesenteric lymph node (C,
F, and I) showing histological changes. (A–C) Macaque CC8X. (D–F) Macaque CC8V. (G–I) Macaque P003. Examination of the spleen, lymph nodes, and
thymus from macaques inoculated with parental SHIVKU-1bMC33 revealed lesions similar to that observed with macaque CC8X.
Fig. 7. Distribution of virus in macaque CC8X. Viral 2-LTR sequences
were amplified using PCR from DNA samples from visceral organs, from
macaque CC8X. The order of the gels shown is as follows: lane 1,
molecular weight markers (100 bp); lane 2, negative control—lymph node
from an uninoculated macaque; lane 3, heart; lane 4, kidney; lane 5, liver;
lane 6, pancreas; lane 7, lung; lane 8, inguinal lymph node; lane 9,
mesenteric lymph node; lane 10, small intestine; lane 11, spleen; lane 12,
thymus; lane 13, positive control—lymph node of macaque 50O; lane 14,
molecular weight markers (100 bp).
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mine viral loads in various organs and to determine if virus
infection resulted in histological lesions in any organs. His-
tological examination of the tissues from macaque CC8V
revealed no lesions in any of the visceral organs examined
or the CNS (Fig. 6). Examination of the visceral organs for
viral 2-LTR sequences revealed that only four of nine or-
Fig. 8. Sequence analysis of the vpu gene from CC8X and CC8V reveals that the S52,56G amino acid substitutions were not stable over the course of the
infection in CC8X. Shown are the predicted amino acid sequences from vpu genes amplified from PBMC DNA samples isolated at various time
postinoculation (A) as well as from the tissue DNA samples (lymph node, spleen, and thymus) obtained at necropsy (B). Sequence ambiguities at particular
positions from the bulk PCR sequencing results are shown above the sequence.
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Fig. 8 (continued)
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gans (inguinal lymph node, mesenteric lymph node, small
intestine, and spleen) were positive for the presence of
2-LTR sequences, respectively (Fig. 9B). The presence of
replicating virus in the lymphoid organs is similar to results
obtained with other SHIV viruses that failed to cause sig-
nificant depletion of CD4 T cells (McCormick-Davis et
al., 2000b; Stephens et al., 2002).
Beginning at 9 months postinoculation, macaque P003
started to develop a loss of appetite and a decrease in the
number of circulating CD4 T cells (500 cells/1 at 9
months to 270 cells/1 at 11 months). This macaque was
euthanized at 11 months in a moribund condition and virus
burdens were analyzed. Virus could not be recovered from
coculturing of PBMC, spleen, lymph node, or thymus cells
with C8166 cells, suggesting very low virus burdens in this
macaque. Histological examination of the tissues from ma-
caque P003 revealed that mesenteric lymph nodes and thy-
mus had undergone severe atrophy, while the spleen had no
significant lesions (Fig. 6). No histological changes or op-
portunistic infections were observed in the heart, kidney,
lung, liver, pancreas, and small intestine that might have
accounted for the animal’s moribund state. Examination of
the visceral organs for 2-LTR sequences revealed that only
five of ten organs (axillary, inguinal, and mesenteric lymph
nodes, small intestine, and spleen) were positive for the
presence of 2-LTR sequences, respectively (Fig. 9A). There
were no histological lesions in the CNS and nested PCR did
not detect gag or 2-LTR sequences in any region of the CNS
of macaque P003 (data not shown).
Macaque P017 was euthanized in good condition at 12
months after inoculation. Virus could not be recovered from
coculturing of spleen, lymph node, or thymus cells with
C8166 cells, suggesting low virus burdens in this macaque.
Histological examination of the tissues (heart, kidney,
lungs, liver, mesenteric lymph nodes, pancreas, spleen,
small intestine, and thymus) from macaque P017 revealed
no significant lesions in any tissues. Examination of the
visceral organs for 2-LTR sequences revealed that only
three of nine organs (mesenteric lymph node, small intes-
tine, and thymus) were positive for the presence of 2-LTR
sequences, respectively (Fig. 9C). There were no lesions in
the CNS and nested PCR did not detect gag or 2-LTR
sequences in any region of the CNS of macaque P017 (data
not shown).
Viral DNA loads in lymphoid tissues at necropsy
correlated with disease progression
We quantified the levels of viral copies in DNA isolated
from the spleen, lymph node, and thymus tissues derived
from macaques CC8X, CC8V, P003, and P017 at necropsy.
As shown in Fig. 10, the levels of viral copies in the spleen,
lymph node, and thymus were 10 to 10,000 times higher in
samples derived from macaque CC8X when compared to
those from the other three macaques, CC8V, P003, or P017.
The number of virus copies in the lymphoid tissues of
macaque CC8X was similar to that observed in two ma-
caques inoculated with parental SHIVKU-1bMC33 (Fig. 10).
Fig. 9. Detection of 2-LTR circles in visceral organs from macaques
CC8V, P003, and P017. DNA was isolated from various visceral organs
and 2-LTR circles were amplified as described in the text. (A) Macaque
P003. (B) Macaque CC8V. (C) Macaque P017. The order of the gel in A
is as follows: lane 1, molecular weight marker (100 bp); lane 2, negative
control—lymph node from an uninoculated macaque; lane 3, kidney; lane
4, liver; lane 5, lung; lane 6, axillary lymph node; lane 7, inguinal lymph
node; lane 8, mesenteric lymph node; lane 9, pancreas; lane 10, small
intestine; lane 11, spleen; lane 12, thymus; lane 13, positive control—
lymph node of macaque 50O; lane 14, molecular weight marker (100 bp).
The order of the gel in B is as follows: lane 1, molecular weight marker
(100 bp); lane 2, negative control—lymph node from an uninoculated
macaque; lane 3, kidney; lane 4, liver; lane 5, lung; lane 6, pancreas; lane
7, inguinal lymph node; lane 8, mesenteric lymph node; lane 9, small
intestine; lane 10, spleen; lane 11, thymus; lane 12, positive control—
lymph node of macaque 50O; lane 13, molecular weight marker (100 bp).
The order of the gel in C is as follows: lane 1, molecular weight marker
(100 bp); lane 2, positive control—lymph node of macaque 50O; lane 3,
negative control—lymph node from an uninoculated macaque; lane 4,
kidney; lane 5, liver; lane 6, lung; lane 7, axillary lymph node; lane 8,
inguinal lymph node; lane 9, mesenteric lymph node; lane 10, spleen; lane
11, small intestine; lane 12, thymus; lane 13, molecular weight marker
(100 bp).
Fig. 10. Analysis of viral DNA copy loads at necropsy in macaques inoculated
with and SHIVKU-1bMC33 and SHIVS52,56G. Total cellular DNA was extracted
from the tissues and used to quantitate the number of viral copies per 106
genorne equivalents in the mesenteric lymph node, spleen, thymus, and PBMC
as described under Materials and Methods. Values designated with (ˆ) indicate
that the gag sequences were detectable but less than one copy was detected per
106 genome equivalents and values designated with a (*) indicate that the viral
gag was not detectable by nested DNA PCR.
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Thus, these results indicated that macaque CC8X, which
developed rapid CD4 T cell loss, also had had the highest
viral copy numbers in lymphoid tissues.
Discussion
Studies have shown that three proteins (Env, Nef, and
Vpu) of HIV-1 can interact with the CD4 molecule and
some investigators have suggested that the CD4 down-
regulation function of Vpu is redundant (Piquet et al., 1998).
The first of the three HIV-1 proteins involved in CD4
down-regulation is the gp160 Env precursor which forms a
complex with the newly synthesized CD4 molecules inside
the rough endoplasmic reticulum (RER) to prevent CD4
traffic to the surface (Crise et al., 1990; Jabbar and Nayak,
1990; Bour et al., 1995). While Nef acts preferentially on
cell surface CD4 (Garcia and Miller, 1991), Vpu acts on
CD4 in the RER to block the trafficking of newly synthe-
sized CD4 molecules to the cell surface membrane (Willey
et al., 1990). While the formation of CD4–gp160 com-
plexes in the ER blocks the maturation and transport of CD4
to the surface, it creates a problem for the virus as the
envelope protein is also blocked from reaching the cell
surface, where it is required for the assembly of infectious
virions (Bour et al., 1995). It has been documented that
synthesis of equimolar amounts of CD4 and Env leads to the
production of noninfectious virions devoid of envelope pro-
tein, as most of the Env is attached to CD4 inside the
endoplasmic reticulum and is simply not available for virion
assembly at the cell surface (Buonocore et al., 1994).
Previous studies have shown that the enhancement of
virion release and degradation of CD4 can be assigned to
different domains of the Vpu protein. While the transmem-
brane domain of Vpu has been shown to be important for
the enhancement of virion release, the cytoplasmic domain
of Vpu has been shown to be important in CD4 degradation
(Schubert et al., 1996a; Paul et al., 1998). Regarding Vpu-
mediated CD4 degradation, phosphorylation of the two ca-
sein kinase II sites in the cytoplasmic domain has been
shown to be essential to this function and it happens to be
the most conserved sequence in Vpu proteins isolated from
different subtypes of HIV-1 (Schubert et al., 1994; Paul et
al., 1997; McCormick-Davis et al., 2000a). The phospho-
serine residues have been shown to interact with the cyto-
plasmic domain of the CD4 molecule in the RER to shunt
CD4 to the proteasome pathway (Fujita et al., 1997; Schu-
bert et al., 1998). Thus, Vpu has a potential role in the
pathogenesis of HIV-1 and SHIV by promoting the degra-
dation of CD4 molecules in these complexes, allowing Env
transport to the cell surface for assembly into viral particles.
Because the Vpu protein is found in HIV-1 and a limited
number of SIV strains, the assessment of the role of Vpu in
HIV-1 pathogenesis using the SIVmac or HIV-2/macaque
models has not been possible. Our laboratory has been using
the SHIV/pig-tailed macaque model system to assess the
role of this gene product in lentiviral pathogenesis. We
showed that during the derivation of a pathogenic variant
from the nonpathogenic SHIV-4 virus that the virus had
accumulated changes within several genes that were asso-
ciated with its newly acquired pathogenesis. Relevant to the
studies reported here, the vpu gene of SHIV-4 did not code
for a functional Vpu as the initiation codon was ACG but
had reverted during derivation of a pathogenic virus (Ste-
phens et al., 1997; McCormick-Davis et al., 1998). Subse-
quently, we developed a molecular clone of one of these
pathogenic variants that caused CD4 T cell loss and AIDS
in pig-tailed macaques. Using this clone, we constructed a
virus (vpuSHIVKU-1bMC33) in which that deletion of the
majority of vpu such that the expressed protein was non-
functional resulted in disease only in one of four macaques
inoculated (McCormick-Davis et al., 2000b). We showed
that the virus from the one macaque that developed neu-
roAIDS had accumulated additional changes in nef and env
that probably compensated for the lack of a functional vpu
gene, whereas the virus isolated from macaques that did not
develop disease had not accumulated consensus changes in
env and nef (Singh et al., 2001). These results suggested that
vpuSHIVKU-1bMC33 was less pathogenic than parental
SHIVKU-1bMC33 but that the virus could continue to evolve
and accumulate amino acid changes within Env and/or Nef
that compensated for the lack of a functional Vpu protein
and attests to the plasticity of the retroviral genome. The
importance of Vpu in the circulating CD4 T cell loss
caused by SHIV was also demonstrated in a recent study of
the entire vpu coding sequence prior to env (Stephens et al.,
2002). Taken together, these studies indicate a role for the
vpu gene product in SHIV and probably HIV-1 pathogene-
sis. Similar to the deletion of Vpu, deletion of other acces-
sory genes, such as nef and/or vpr, from SIVmac results in
viruses with attenuated pathogenicity (Daniel et al., 1992;
Desrosiers et al. 1998) that may require longer periods of
time to cause disease (Baba et al., 1995; Hofmann-Lehman
et al., 2003). Both of these genes are considered to contrib-
ute to the pathogenicity of SIV and HIV-1. Similarly, we
believe that deletion of the vpu gene results in an attenuated
virus that in certain circumstances can evolve to compensate
for the lack of this gene. Taken together, these results
emphasize that pathogenicity caused by HIV-1, SIV, or
SHIV is multigenic in nature and that Vpu contributes to the
pathogenicity of SHIV and HIV-1.
In this report, we have analyzed the ability of the patho-
genic molecular clone SHIVKU-1bMC33 to cause rapid CD4
T cell loss and AIDS following site-directed changes that
removed the two casein kinase II phosphorylation sites in
the cytoplasmic domain of the Vpu protein. Using a
VpuEGFP reporter system, we showed that the protein was
localized to the same compartments as the unmodified pro-
tein, had a similar stability in cells, but was incapable of
promoting CD4 degradation. We hypothesized that because
of the importance of the casein kinase II sites to CD4
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degradation by Vpu that the virus would be less pathogenic
for macaques. We found that one of four macaques inocu-
lated with SHIVS52,56G developed a rapid CD4 T cell loss
that is typically observed with pathogenic SHIV, whereas
all four macaques inoculated with the parental SHIVKU-
1bMC33 virus developed rapid CD4 T cell loss within 1
month which was maintained for up to 6 months postinocu-
lation. These results indicate that the casein kinase II sites of
the Vpu protein are important to the massive CD4 T cell
loss associated with infection with this virus. The obvious
question that arose from the results of this study was “Why
did macaque CC8X develop severe CD4 T cell loss and
die at 18 weeks postinoculation?” We hypothesized that the
virus in this macaque may have selected for mutations in
vpu that might have resulted in the reversion of the glycines
at positions 52 and 56 to serine residues or compensating
amino acid substitutions in other proteins, such as Env.
Sequence analysis of bulk PCR that amplified vpu and
individual vpu clones at different time points postinocula-
tion was used to determine if there was a reversion of the
glycine residues back to serines. The results of the bulk PCR
sequencing indicate a reversion first at position 56 and later
at position 52. While we were only able to detect the
reversions beginning at 3 weeks in the PBMC, which was
several weeks after the severe CD4 T cell loss occurred,
the mutations that we observed in the PBMC may have
followed what had occurred earlier in primary and second-
ary lymphoid tissues. Interestingly, the thymus contained
only the input viral sequences, whereas the spleen and
lymph nodes had a mixture of the viruses. Because these
results were based on PCR amplification of the vpu genes
from isolated DNA, we also analyzed the virus that was
recovered from the mesenteric lymph nodes, spleen, thy-
mus, and PBMC obtained at necropsy. Our results indicated
that the reversions were present in infectious cytopathic
viruses recovered from these tissues, providing additional
evidence that selection for these mutations had occurred in
macaque CC8X. The reversions observed in macaque
CC8X are reminiscent of the changes that occurred in the
derivation of a pathogenic variant from the original non-
pathogenic SHIV-4 (Joag et al., 1996; Stephens et al., 1997;
McCormick-Davis et al., 1998) and provide another exam-
ple that a “functional Vpu” makes the pathogenic SHIV a
more “fit” virus, possibly by giving such a virus a replica-
tive advantage over other quasispecies in the same macaque
lacking a functional Vpu. Taken together, the results of this
study indicate for the first time that the phosphorylation of
Vpu potentiates a dramatic loss in CD4 T cells following
inoculation with pathogenic SHIVKU-1bMC33 and provide
additional evidence that this viral protein is important to the
CD4 T cell loss in HIV-1-infected people. The results of
this study also reinforce the utility of the SHIVKU-1bMC33/
pig-tailed macaque model for analyzing the role of various
amino acids/domains in the Vpu in HIV-1 pathogenesis.
Materials and methods
Cells, plasmids, and viruses
The C8166 cell line was used as the indicator to measure
the infectivity and cytopathicity of the viruses used in this
study. C8166 cells were maintained in RPMI 1640, supple-
mented with 10 mM HEPES buffer, pH 7.3, 2 mM glu-
tamine, 5 g/ml of gentamicin, and 10% fetal bovine serum
(R10FBS). The derivation of SHIVKU-1bMC33 has been pre-
viously described (Narayan et al., 1999; McCormick-Davis
et al., 2000b; Stephens et al., 2002).
Construction of VpuEGFP, VpuS52,56GEGFP, and EGFP
expression vectors
In order to construct the VpuEGFP vector for expression
studies, the vpu gene from SHIVKU-1bMC33, which has a
fully functional vpu gene, was amplified from infected cells
using PCR and oligonucleotides 5-TGTAATGCAAC-
CTATACCAATAGTAGCA-3 (sense strand, at the 5 end
of the gene) and 5-TCCATGGGATCATCAACATC-
CCAAGTAGC-3 (antisense and also containing an NcoI
site). One microgram of genomic DNA was used in the PCR
containing 1.4 mM MgSO4, 200 M each of the four de-
oxynucleotide triphosphates, 100 pM each oligonucleotide
primer, and a mixture of Taq and Pyrococcus species GB-D
polymerases (Elongase, GibcoBRL). The template was de-
natured at 94°C for 2 min and PCR amplification performed
with an automated DNA Thermal Cycler (Perkin–Elmer
Cetus) for 35 cycles using the following profile: denatur-
ation at 94°C for 30 s, annealing at 65°C for 1 min, and
primer extension at 68°C for 5 min. Amplification was
completed by incubation for 10 min at 68°C. The amplified
fragment, which is approximately 250 bases in length, was
cloned into the pGEM-T vector (Promega) according to the
manufacturer’s instructions. Recombinants were identified
and inserts sequenced in their entirety to ensure that no
sequence errors were introduced during the amplification
process. This plasmid, known as pvpuNcoI, was digested to
completion using the restriction endonuclease NcoI; the vpu
gene fragment was gel purified and subcloned into NcoI-
digested CIAP treated pEGFP vector (Clontech Laborato-
ries; Cormack et al., 1996) that has an NcoI site at the 5 end
of the EGFP gene. The resulting plasmid, known as
pvpuEGFP, was sequenced to ensure that (1) the vpu gene
was inserted in the proper orientation and (b) the vpu/EGFP
junction was in-frame. The vpuEGFP fusion gene was then
inserted into the pcDNA3.1() vector for expression stud-
ies. The pvpuEGFP vector was digested to completion with
KpnI and StuI, which cuts on either side of the insert. The
insert was gel purified and subcloned into the
pcDNA3.1(), which was also digested with KpnI and
EcoRV. The resulting plasmid, pcvpuEGFP, contained the
entire vpu gene fused to the gene for EGFP under the
control of the CMV immediate early promoter. A similar
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plasmid was constructed which expressed only the EGFP
protein (pcEGFP).
To determine if VpuEGFP was phosphorylated, we al-
tered the two serine residues that were previously reported
to be phosphorylated by casein kinase II to glycine residues.
This was performed using two rounds of mutagenesis. The
oligonucleotide primers used in the first round were 5-
GAAAGAGCAGAAGACGGTGGCAATGAGAGTGAAG-
3 (sense) and 5-CTTCACTCTCATTGCCACCGTCTTC-
TGCTCTTTC-3 (antisense), which changed the serine at
position 52 to a glycine residue. In the second round of mu-
tagenesis, the oligonucleotide primers used were 5-GACG-
GTGGCAATGAGGGTGAAGGAGAAATATC-3 (sense)
and 5-GATATTTCTCCTTCACCCTCATTGCCACCGT-
C-3 (antisense), which changed the serine residue at posi-
tion 56 to a glycine residue. The mutagenesis protocols were
identical to those described above. A plasmid designated
pcvpuS52,56GEGFP was isolated and the VpuEGFP insert
sequenced to ensure that the correct mutation was intro-
duced and that no additional mutations were accidentally
introduced. This insert was then inserted into the
pcDNA3.1() vector as described above, designated
pcvpuS52,56GEGFP, and used in expression studies.
Transfection and intracellular location studies
VpuEGFP and other mutants were transfected in human
293 cells to assess their subcellular localization using a
cationic polymer (polyethylenimine) transfection reagent
(ExGen 500, MBI Fermentas) using the manufacturer’s
protocol. Briefly, 1–3  105 cells were seeded into each
well of a six-well tissue culture plate 24 h prior to transfec-
tion. Transfection was carried out on cultures that were
50–60% confluent using 9.5 g of plasmid DNA and 26 l
of ExGen 500 corresponding to 5 equivalents. Each plasmid
sample and polyethylenimine were diluted in 75 l of 150
mM sodium chloride solution separately. Samples were
vortexed gently and immediately centrifuged at low revo-
lution for a few seconds. Polyethylenimine was then added
to the plasmid DNA solution, mixed with a vortex, and
allowed to stand at room temperature for 10 min. The 293
cells were washed with serum-free media twice and added
with 1.5 ml of serum-free DMEM. Polyethylenimine/DNA
mixture was added to the cells and the plate swirled by slow
hand rotation for a couple of seconds. Culture plates were
centrifuged at 280  g for 5 min and incubated at 37°C for
30 min. The medium from transfected cultures was replaced
with fresh complete growth media and cells were incubated
at 37°C in a 5% CO2 atmosphere. Transfected cells were
observed by confocal microscopy, which is known to have
the advantage that fluorescence can be detected from cells in
different layers. For confocal microscopy, 293 cells were
plated and transfected on two-well Lab-Tek chamber slides.
To prepare cells for detection of EGFP fluorescence, the
medium was removed after 48 h following transfection, the
monolayers were briefly rinsed in PBS, and the cells fixed
for 10 min at room temperature in freshly prepared 1%
paraformaldehyde in PBS. The upper chambers of the slides
were removed and fixed cells were treated with Prolong
Anti-Fade (Molecular Probes, Eugene, OR) and mounted
under a coverslip. Images were collected using a Zeiss
Confocal Laser Scanning Microscope, LSM-510, using an
excitation wavelength of 488 nm with a LP-505 emission
filter. Images were analyzed and three-dimensional recon-
structions of the subcellular localization of the VpuEGFP
mutants were generated using LSM-510 software.
CD4 staining
To determine if the VpuEGFP construct was capable of
promoting degradation of CD4 in transfected cells, we em-
ployed HeLa CD4 cells. Briefly, HeLa CD4 cells were
grown on coverslips and transfected with pcvpuEGFP as
described earlier. At 48 h posttransfection, cells were
washed twice with wash buffer (PBS, pH 7.2, containing
2% fetal calf serum and 0.01% NaN3) and reacted with
mouse anti-CD4 (clone SFCI12T4D11CD4, Beckman-
Coulter, 1:500 dilution) for 45 min. After the incubation,
coverslips were washed three times and incubated with
rhodamine-conjugated secondary antibody (goat, Chemi-
con, 1:50 dilution) for 35 min followed by washing five
times in buffer without serum. Cells were then fixed in 1%
formalin for 10 min, washed twice, equilibrated with anti-
fade buffer, and mounted on microscope glass slides using
Anti-Fade (Molecular Probes). Cells were immediately ob-
served under a fluorescent microscope (Nikon TE300) with
a fluorescein filter (for visualization of EGFP) and rhoda-
mine filters (for visualization of CD4 staining). All the
staining procedures were performed on ice and in the dark.
HeLa CD4 cells transfected with EGFP alone served as
controls for down-regulation of CD4 and cultures of HeLa
CD4 cells treated with wash buffer instead of primary
antibody served as negative controls for CD4 staining. A
minimum of 400 EGFP expressing cells were counted.
Construction of SHIVS52,56G
A virus was constructed in which vpu was mutated such
that the serines at positions 52 and 56 of Vpu were changed
to glycine residues. Plasmid pUC19 SNvpu12, containing
the SphI to KpnI fragment of SHIVKU-1bMC33 in pUC-19
(and coding for the tat, rev, vpu, and 5 end of env) was used
for the site-directed mutagenesis studies, which were per-
formed in two steps. In the first round of mutagenesis,
oligonucleotides 5-GAAAGAGCAGAAGACGGTGGCA-
ATGAGAGTGAA-3 (sense) and 5-CTTCACTCTCATT-
GCCACCGTCTTCTGCTCTTTC-3 (antisense) were used
to change the serine at position 52 to a glycine residue. The
plasmid used was pUC19 SNvpu12 with the Quick-Change
Mutagenesis Kit (Stratagene) according to the manufactur-
er’s instructions. In the second round of mutagenesis,
oligonucleotides 5-GACGGTGGCAATGAGGGTGAAG-
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GAGAAATATC-3 (sense) and 5-GATATTTCTCCTTC-
ACCCTCATTGCCACCGTC-3 (antisense) were used to
change the serine at position 56 to a glycine. Clones and
plasmids were isolated and the entire insert was sequenced
to determine if the mutations were introduced as expected
and to ensure that no additional changes were introduced
during the mutagenesis step. A plasmid was isolated and
designated pvpuS52,56G that contained the desired mutations.
This plasmid was digested to completion with SphI/KpnI,
and the 450-bp fragment isolated and subcloned into
the p3SHIVKU-1bMC33 plasmid as previously described
(McCormick-Davis et al., 2000b). The resulting plasmid,
p3SHIVS52,56G, was used to construct an infectious virus
known as SHIVS52,56G using procedures previously de-
scribed (Stephens et al., 1998; Liu et al., 1999; McCormick-
Davis et al., 2000b; Singh et al., 2002). Stocks of the virus
were prepared and titered in C8166 cells. The virus stock
was examined by PCR amplification of the vpu gene se-
quence and sequence analysis to ensure the purity of the
stock virus. We also sequenced the tat, rev, env, and nef
genes to ensure that they were identical to the parental
SHIVKU-1bMC33 sequence.
p27 assays
Standard p27 assays were used to assess release of viral
particles from cells infected with SHIVS52,56G or parental
SHIVKU-1bMC33. Cultures of 106 C8166 cells were inocu-
lated with equivalent amounts (30 ng) of cell-free virus
stocks for 2 h. At the end of 2 h the cells were centrifuged
at 400  g for 10 min and the pellet was washed with 10 ml
of medium. This was repeated two additional times. The
cells were resuspended in RPMI 1640 supplemented with
10% FBS and antibiotics and this was considered the 0 time
point of the assay. Cultures were incubated at 37°C and
aliquots of the culture were removed at 0, 1, 3, 5, 7, and 10
days. The culture medium was separated from the cells by
centrifugation and then assayed for p27 according to the
manufacturer’s instructions.
Macaques analyzed in this study
Four pig-tailed macaques (CC8X, CC8V, P003, and
P017) were inoculated intravenously with 1 ml of undiluted
supernatant from C8166-grown stocks of SHIVS52,56G con-
taining approximately 104 TCID50/ml as previously de-
scribed (McCormick-Davis et al., 2000b). At 4 months
postinoculation, macaque CC8X became anemic (hemoglo-
bin 5.7 g/dl, mean cell packed volume of 18%), developed
thrombocytopenia (28,000 per/liter) and pectaheal hemor-
rhages, and was euthanized in a moribund condition at 18
weeks postinoculation. Macaque CC8V did not develop
significant CD4 T cell loss and was sacrificed at 9 months
in a healthy condition with normal CD4 T cell counts for
examination of virus burdens. Macaque P003 developed a
wasting condition starting at 10 months postinoculation and
was subsequently euthanized at 11 months postinoculation.
Macaque P017 maintained circulating CD4 T cell levels in
the normal range and was euthanized in a heathly condition
12 months postinoculation. Four additional macaques
(2000, 2001, CM4G, and CM4K) were inoculated with 1 ml
of parental SHIVKU-1bMC33 (104 TCID50) and circulating
CD4 T cell counts followed for at least 6 months. Ma-
caques CM4G and CM4K were euthanized at 6 months after
inoculation and analyzed for virus content and SHIV-asso-
ciated pathology.
Processing of blood samples
PBMC were prepared by centrifugation on Ficoll–
Hypaque gradients as described previously (Joag et al.,
1996). Tenfold dilutions of PBMC (106 cells/ml) were in-
oculated into replicate cultures of C8166 cells in 24-well
plates and the cocultures examined for development of
cytopathic effects as previously described (McCormick-
Davis et al., 2000b). Infectivity titers in plasma were re-
ported as TCID50/ml and cells producing infectious cyto-
pathic virus in the blood reported as the number of infected
cells/106 PBMC. Alterations in CD4 and CD8 T lym-
phocytes after experimental inoculations were monitored
sequentially by FACS analysis (Becton–Dickinson). T lym-
phocyte subsets were labeled with OKT4 (CD4; Ortho
Diagnostics Systems, Inc.), B9.11 (CD8; Coulter Immunol-
ogy), and SP34 (CD3; Pharmingen), or FN18 (CD3; Bio-
source International) monoclonal antibodies.
Processing of tissue samples at necropsy
At the time of euthanasia, all animals in this study were
anesthetized by administration of 10 mg/kg of ketamine
(im) followed by an intravenous administration of sodium
pentobarbital at 20–30 mg/kg. A laparotomy was performed
and the animal exsanguinated by aortic canulation. The
chest was opened, the left ventricle canulated, the right
atrium nicked, and the animal perfused with 1 liter of cold
pyrogen-free Ringer’s saline. All aspects of the animal stud-
ies were performed according to the institutional guidelines
for animal care and use at University of Kansas Medical
Center. At necropsy, tissues from the axillary lymph nodes,
heart, kidney, liver, lungs, mesenteric lymph nodes, pan-
creas, small intestine, spleen, and thymus were fixed in 10%
neutral buffered formalin and embedded in paraffin. Sec-
tions (5 m) were stained with hematoxylin and eosin for
routine histological examination. In addition, the right
halves of the brain and spinal cord were dissected into
frontal, motor, parietal, temporal, and occipital cortices; the
corpus callosum, thalamus, basal ganglia, midbrain, pons,
medulla, cerebellum, and cervical, thoracic, and lumbar
spinal cord were also processed as above. Portions of each
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of the visceral organs and the CNS were also frozen in
liquid nitrogen for molecular virological analysis.
PCR amplification and sequence analysis of vpu, env, and
nef sequences
Because potential reversion of the glycine residues at
positions 52 and 56 to serine residues may have occurred
following inoculation with SHIVS5256G or mutations may
have occurred in other genes, such as env and nef, that
compensated for the loss of Vpu function, we analyzed vpu,
env, and nef sequences at different times following inocu-
lation of macaque CC8X with SHIVS52,56G and compared
these sequences to those from SHIVKU-1bMC33. PBMC were
collected at 3, 8, 12, and 18 weeks (necropsy) after inocu-
lation and DNA extracted as previously described (McCor-
mick-Davis et al., 2000b). For analysis of vpu and gp120
sequences, oligonucleotide primers 5-CCTAGACTAGA-
GCCCTGGAAGCATCC-3 and 5-AGTGCTTCCTGCT-
GCTCCCAAGAACCC-3 were used, which are comple-
mentary to nucleotides 5845 to 5870 and 7781 to 7810 of
the HIV-1 (HXB2) genome (Ratner et al., 1985), respec-
tively. One microgram of genomic DNA was used in the
PCR (Saiki et al., 1985, 1988) containing 1.4 mM MgSO4,
200 M each of the four deoxynucleotide triphosphates, 100
pM each oligonucleotide primer, and a mixture of Taq and
Pyrococcus species GB-D polymerases (Elongase, Gibco-
BRL). The template was denatured at 94°C for 2 min and
PCR amplification performed with an automated DNA
Thermal Cycler (Perkin–Elmer Cetus) for 35 cycles using
the following profile: denaturation at 94°C for 30 s, anneal-
ing at 65°C for 1 min, and primer extension at 68°C for 5
min. Amplification was completed by incubation for 10 min
at 68°C. Three separate PCRs were performed for each
region of viral genome that was studied. The amplified
products from three separate reactions were separated by
electrophoresis in a 1% agarose gel, isolated, and molecu-
larly cloned into the pGEM-T Easy vector according to the
manufacturer’s instructions. Cycle sequencing reactions us-
ing the BigDye Terminator Cycle sequencing Ready Reac-
tion kit with AmpliTaq DNA polymerase, FS (PE Applied
Biosystems, Foster City, CA) and sequence detection was
conducted with an Applied Biosystems 377 Prism XL au-
tomated DNA sequencer and visualized using the ABI Edit-
view program.
For amplification of nef, oligonucleotide primers 5-CCA-
CATACCTAGAAGAATAAGACAGGG-3 (sense) and
5-ACATCCCCTTGTGGAAAGTCCCTGCTGTTT-3 (anti-
sense) were used, which are complementary to nucleotides
8746 to 8772 of the HIV-1 (HXB2) genome (Ratner et al.,
1985) and 9868 to 9898 of the SIVmac239 genome (Regier and
Desrosiers, 1990), respectively. The conditions for amplifica-
tion, cloning, and sequencing of the PCR products were as
described above.
PCR analysis of tissues for the presence of viral
sequences
SHIV gag
Visceral organs (ileum, lymph nodes, spleen, lung, liver,
and thymus) were collected and DNA was isolated as de-
scribed below. The brain and spinal cord from infected
macaques CC8X, CC8V, P017, and P003 were taken at
necropsy and dissected into the following regions: frontal
cortex, parietal cortex, occipital cortex, motor cortex, tem-
poral cortex, corpus callosum thalamus, basal ganglia, mid-
brain, pons, medulla, cerebellum, cervical spinal cord, tho-
racic spinal cord, and lumbar spinal cord. The tissues were
homogenized in a tight-fitting Dounce homogenizer in the
presence of TE buffer (50 mM Tris–HCl, pH, 8.2, 10 mM
EDTA) and 0.5% SDS. The homogenate was digested at
37°C for 2 h in the presence of 100 g/ml of proteinase K
followed by extraction twice with an equal volume of phe-
nol and once with chloroform:isoamyl alcohol. The DNA in
the aqueous phase was precipitated with 2 vol of ethanol,
pelleted, and resuspended in DNase-free H2O. We used
nested PCR to determine if SIV gag sequences were present
in the DNA isolated from the various tissues (Joag et al.,
1994). In the first round, the SIV oligonucleotide primers
used were 5-GATGGGCGTGAGAAACTCCGTCTT-3
(sense) and 5-CCTCCTCTGCCGCTAGATGGTGCTGT-
TG-3 (antisense), which are complementary to bases 1052
to 1075 and 1423 to 1450 of the SIVmac239 gag gene,
respectively (Regier and Desrosiers, 1990). As an internal
control, separate PCRs were performed in which the fourth
exon of -actin was amplified with oligonucleotide primers
5-TCATGTTTGAGACCTTCAACACCCCAG-5(sense)
and 5-CCAGGAAGGAAGGCTGGAAGAGTGCC-5 (anti-
sense) complementary to the published sequence
(Nakijima-Iijima et al., 1985). The PCR amplification was
performed using the following conditions: denaturation at
92°C for 1 min; annealing at 55°C for 1 min; and primer
extension at 72°C for 3 min. To increase the sensitivity of the
reaction, 1 l of the first PCR product was used as a template
for a second amplification using the same conditions. The
nested SIV primers used were 5-GTACATGTTGAAGCAT-
GTAGTATGGGCAGC-3 (sense) and 5-CACCACTAG-
GTGTCTCTGCACTATGTGTTTTGC-3 (antisense). The
nested -actin primers used were 5-CCCCAGCCATG-
TACGTTGCTATCC-3 (sense) and 5-GCCTCAGGGCA-
GCGGAACCGCTCA-3 (antisense). Samples were amplified
for another 35 cycles as described above. Following the second
round of amplification, a 10-l aliquot was removed and run
on a 1.5% agarose gel and bands were visualized by staining
with ethidium bromide.
Detection of SHIV long terminal repeat (LTR) circles
Examination of 2-LTR circular DNA provides a view of
a spreading infection based on a viral DNA form that is
structurally distinct and known to have a short half life in
449D.K. Singh et al. / Virology 313 (2003) 435–451
infected cells (Pauza et al., 1994; Zazzi et al., 1997; Teo et
al., 1997; Sharkey et al., 2000; Sharkey and Stevenson,
2001). We analyzed the DNA isolated from PBMC, ileum,
liver, lymph node, lung, and spleen and the 14–15 regions
of the CNS for the presence of 2-LTR circular forms of
DNA as previously described (McCormick-Davis et al.,
2000b). The oligonucleotides used in the first round were
5-ATTTCGCTCTGTATTCAGTCGCTCTGC-3 (U5 re-
gion) and 5-CCTCCTGTGCCTCATCTGATACATTTA-
C-3 (U3 region), which correspond to bases 10335 to
10361 and 180 to 153 of the SHIV genome, respectively.
The PCR amplification was performed using the following
conditions: denaturation at 92°C for 1 min; annealing at
55°C for 1 min; and primer extension at 72°C for 3 min.
One microliter of the first PCR product was used as a
template for a second amplification using the same condi-
tions. The oligonucleotide primers used for the second
round were 5-AGGTTCTCTCCAGCACTAGCAGGTAG-
AGC-3 (U5 region) 5-TTGGGTATCTAATTCCTGGTC-
CTGAG-3 (U3 region; opposite strand; 456), which corre-
spond to bases 10389 to 10417 and 120 to 95 of the SHIV
genome, respectively. Samples were amplified for another
35 cycles as described above. Following the second round
of amplification, a 10-l aliquot was removed and run on a
1.5% agarose gel and bands were visualized by staining
with ethidium bromide. The predicted product of the 2-LTR
PCR product is 361 bp.
Analysis of virus loads in macaques
PCR–ICA
The virus loads in the lymphoid tissues (spleen, lymph
nodes, thymus, PBMC) were determined using a quantita-
tive PCR assay modified from a PCR-infected cell assay
previously described (Joag et al., 1994; Stephens et al.,
1998). In this assay, 1 g of total cellular DNA isolated
from tissues was subjected to a series of 10-fold dilutions
such that samples contained from 100 ng to 10 fg (less than
one copy of chromosomal DNA). These samples were used
in nested PCR reactions that amplified either the -actin
gene of the cell (a single copy gene) or the gag gene from
SIVmac239. Amplification of either gene using the primers
previously described was shown to detect one copy of each
gene (Joag et al., 1994). Thus amplification of the -actin
gene determined the number of genome equivalents in each
sample, while amplification with the gag primers deter-
mined the number of viral copies per number of genome
equivalents. The values were expressed as the number of
viral copies per 106 genome equivalents.
Plasma virus RNA loads
Plasma viral RNA loads were determined on RNA ex-
tracted from 500 liters of EDTA -treated plasma. Virus was
pelleted and RNA extracted using the Qiagen viral RNA kit
(Qiagen, Valencia, CA). RNA samples were analyzed by
real-time RT–PCR using gag primers and a 5FAM- and
3TAMRA-labeled Taqman probe that was homologous to
the SIV gag gene as previously described (Hofman-Leh-
mann et al., 2000). Standard curves were prepared using a
series of six 10-fold dilutions of viral RNA of known
concentration. The sensitivity of the assay was 100 RNA
equivalents/ml. Samples were analyzed in triplicate and the
numbers of RNA equivalents were calculated per milliliter
of plasma.
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